Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors (vol 38, pg 160, 2020)

Sadal Refae; Jocelyn Gal; Nathalie Ebran; Josiane Otto; Delphine Borchiellini; Frederic Peyrade; Emmanuel Chamorey; Patrick Brest; Gerard Milano; Esma Saada-Bouzid

doi:10.1007/s10637-020-00954-x

Back

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors (vol 38, pg 160, 2020)

Journal article

Open access

Peer reviewed

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors (vol 38, pg 160, 2020)

Sadal Refae, Jocelyn Gal, Nathalie Ebran, Josiane Otto, Delphine Borchiellini, Frederic Peyrade, Emmanuel Chamorey, Patrick Brest, Gerard Milano and Esma Saada-Bouzid

Investigational new drugs, Vol.39(1), pp.287-292

01/02/2021

DOI: https://doi.org/10.1007/s10637-020-00954-x

PMID: 32500464

Abstract

Life Sciences & Biomedicine

Oncology

Pharmacology & Pharmacy

Science & Technology

Corrections are needed to the original version of this article.

Files and links (1)

url

https://doi.org/10.1007/s10637-020-00954-xView

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors (vol 38, pg 160, 2020)
Creators - without role: Sadal Refae - Centre Antoine Lacassagne
Jocelyn Gal - Centre Antoine Lacassagne
Nathalie Ebran - Centre Antoine Lacassagne
Josiane Otto - Centre Antoine Lacassagne
Delphine Borchiellini - Centre Antoine Lacassagne
Frederic Peyrade - Centre Antoine Lacassagne
Emmanuel Chamorey - Centre Antoine Lacassagne
Patrick Brest - Centre Antoine Lacassagne
Gerard Milano - Centre Antoine Lacassagne
Esma Saada-Bouzid - Centre Antoine Lacassagne
Publication Details: Investigational new drugs, Vol.39(1), pp.287-292
Publisher: Springer Nature
Number of pages: 6
Identifiers: 9921851808331
Language: English
Resource Type: Journal article